How OR6A2 and octanal on monocytes relate to outcomes after myocardial ischemia-reperfusion injury

Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury

This project tries to see if the OR6A2 receptor on monocytes and blood levels of octanal are linked to inflammation and later heart complications in people who had myocardial ischemia-reperfusion injury after PCI.

Quick facts

• Study type: Observational
• Enrollment: 200 (estimated)
• Ages: 18 Years to 90 Years
• Sex: All
• Sponsor: Southeast University, China (other)
• Locations: 1 site (Nanjing, Jiangsu)
• Trial ID: NCT07100457 on ClinicalTrials.gov

What this trial studies

This is an observational study of patients who experienced myocardial ischemia-reperfusion injury after primary percutaneous coronary intervention. Investigators measure OR6A2 expression on monocyte subtypes, plasma octanal, and systemic oxidative stress and inflammatory biomarkers from blood samples taken after revascularization. They then correlate these molecular profiles with major adverse cardiovascular events identified during a 44-month clinical follow-up. The goal is to identify biomarker patterns that predict clinical outcomes and could support personalized risk stratification after revascularization.

Who should consider this trial

Good fit: Ideal candidates are adults (age 18–90) with angiographically confirmed coronary artery disease who had an acute myocardial infarction treated with primary PCI and were diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.

Not a fit: Patients with active systemic infections, advanced heart failure (NYHA class III–IV), acute cerebrovascular events, myocarditis, cardiomyopathy, refractory ventricular arrhythmias, recent malignancy treatment, severe renal failure (eGFR <30 or dialysis), or Child-Pugh class C liver disease are excluded and unlikely to receive benefit from participation.

Why it matters

Potential benefit: If successful, the findings could identify blood biomarkers that help predict which patients are at higher risk for complications after revascularization and guide more personalized follow-up or treatment.

How similar studies have performed: This line of inquiry is relatively novel—olfactory receptor signaling on immune cells like OR6A2 is an emerging area with limited direct clinical data, although biomarker correlations with inflammation and outcomes after reperfusion have been reported in related work.

Eligibility criteria

Inclusion Criteria:

1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.
2. Age 18-90 years inclusive.

Exclusion Criteria:

1. Active systemic infections.
2. Advanced heart failure (NYHA class III-IV).
3. Acute cerebrovascular conditions.
4. Active myocarditis.
5. cardiomyopathy.
6. Refractory ventricular tachycardia/fibrillation.
7. Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ).
8. Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m2 or dialysis dependence).
9. Child-Pugh class C hepatic dysfunction.

Where this trial is running

Nanjing, Jiangsu

• Department of Cardiology, Zhongda Hospital, Southeast University — Nanjing, Jiangsu, China (RECRUITING)

Study contacts

• Study coordinator: Wenbin Lu, PhD

Conditions: Myocardial Ischemia-Reperfusion Injury